

## Lung-MAP S1400 Lung Master Protocol Update Meeting

Friday, September 16, 2016 2:15 to 3:45 pm

Hyatt Regency Chicago
Regency D (West Tower, Gold Level)

Agenda

Welcome Karen Kelly, MD

**SWOG Lung Committee Chair** 

Study Updates Vassiliki (Vali) Papadimitrakopoulou, MD

Study Chair, Medical Oncology

Study Logistics / Mary Redman, PhD

**S1400l Patient Reported Outcomes** Lead Biostatistician

Quality Assurance and Monitoring Elaine Armstrong, MS

SWOG Quality Assurance Manager

Accrual Enhancement Committee Roy Herbst, MD, PhD

Study Co-Chair, Medical Oncology

Site Coordinators Committee Jessica Jordan, BA

Site Coordinator Committee Chair

Questions and Answers David Gandara, MD

Study Co-Chair, Moderator





## **S1400 Registration and Study Flow**

Screen for eligibility, consent patient and confirm that required amount of tissue is available for submission (pathologist must complete the \$1400 Local Pathology Review Form) Register to \$1400 in OPEN\* Submit tissue specimen to Foundation Medicine, Inc. within 1 day after registration and log shipment in SWOG Specimen Tracking System If pre-screening prior to progression If screening at progression When patient progresses, submit Notice of Progression\* Within 16 days after tissue submission Within 1 day after form submission (provided at least 16 days have passed since tissue submission) Site staff receives email with sub-study assignment\* (Assignment will also display in the Sub-study Assignment Form in Rave®) Evaluate/confirm sub-study common eligibility and sub-study specific eligibility criteria If patient IS eligible for and If patient is **NOT** eligible for any consents to assigned sub-study sub-study If patient meets sub-study common eligibility criteria but Register to S1400X sub-study in OPEN does **NOT** meet sub-study Submit Notice of Intention not after receiving sub-study assignment specific eligibility criteria to Register Form in Rave® email Administer protocol treatment within 7 working days of sub-study Follow and submit required Submit Request for Sub-study registration, conduct follow-up, obtain forms until 3 years from Reassignment Form in Rave® and submit specimens, radiology images registration or death (whichever and forms per sub-study protocol comes first) per S1400 screening protocol Submit S1400 Request for Patient progresses on S1400X New Sub-study Assignment sub-study and is potentially Form in Rave® eligible for another sub-study A LUNG-MAP

<sup>\*</sup>If it is determined that a patient will not register to a sub-study at any time following S1400 registration, the *Notice of Intention Not to Register* form must be submitted. Should the decision to not register a patient to their assigned sub-study be reversed, sub-study registration <u>is</u> allowed despite submission of the *Notice of Intention Not to Register* form.



## LUNG-MAP S1400 Site Coordinator Committee

The Lung-MAP Site Coordinator Committee (SCC) was formed in July 2016. The members are site staff from a variety of institutions, NCTN affiliations, and geographical locations who work closely with the study leadership. The members provide recommendations and feedback on accrual strategies, patient and promotional materials, changes to study procedures, data collection, and staff training materials. Look for their face or name on their badge and let them know your concerns, questions, or helpful advice for making Lung-MAP collaborative and successful. You can also contact them at LungmapSCC@crab.org.



Joan Aresco joan.aresco@stjoeshealth.org 734-712-3304

**ECOG-ACRIN** 



Jamie Arnett, BSN, RN, OCN arnettj@somc.org 740-356-7594

Alliance



Wanda M. Burdette RN, OCN, CCRP wburdette@gibbscc.org 864-560-6810

SWOG



Co-Chair Lavinia Dobrea RN, MS, OCN Lavinia.Dobrea@stjoe.org 714-734-6214

NRG



Chair Jessica Jordan, BA jessica.jordan@va.gov 203-932-5711 ext 3287

Veteran's Affairs Connecticut / **SWOG** 



Steffany Lim, CCRP sllim@ucdavis.edu 916-734-0561

**SWOG** 



Kathy Malatesta, RN, OCN, CCRC kathy.malatesta@mainegeneral.org 207-626-4855

Alliance



Joan Moore, MSN, RN, OCN, CCRP jmoore@wellspan.org 717-339-2638

NRG



Nichole Rykbos 901-326-8359 Nichole.Rykbos@BMHCC.org

Minority/SWOG



Stephanie Smith, RN, MSN, OCN smiths1@sichs.org 912-819-5723

**ECOG-ACRIN** 



Tyler Workman, RN, MSN tworkman@queens.org 808-691-8583

Minority/SWOG

# Study requirement

## TUMOR CONTENT ≥ 20%

including tumor volume  $\geq 0.2 \text{ mm}^3$ 

It is important that the specimen contains as much tumor content as possible to ensure that there's enough DNA needed for sequencing.



#### **<u>\$1400</u>** requires adequate tissue for biomarker profiling.

For details, please refer to the **S1400** protocol Section 5 for eligibility requirements and Section 15 for a complete description of tissue requirements. Specimens must be submitted using the SWOG Specimen Tracking System, a process outlined in the **S1400** protocol Section 15.

#### **NOTE FOR LIVER SPECIMENS:**

It is recommended that at least 40% of the specimen contain malignant cells to ensure sufficient tumor DNA.


#### For Best Results, Use These Specifications OR SPECIMEN TYPE FFPE BLOCK or 12-20 SLIDES (+H&E SLIDE) Tissue must be formalin-fixed and paraffin embedded. A tissue block is preferred. • If sending slides: **BLOCK SLIDES** - A minimum of 12 unstained, charged, and unbaked 4-5 micron slides are required. -20 slides are highly recommended. SURFACE AREA ≥ 25 mm<sup>2</sup> SPECIMEN VOLUME ≥ 1 mm<sup>3</sup> - Slides should include an additional H&E or The face of the block or slide (including tumor volume $\geq 0.2 \text{ mm}^3$ ) Aperio stained slide (If unavailable, submit should be at least 25 mm<sup>2</sup> an extra unstained slide). The total volume (surface area x depth) of the in area (for example, • For core biopsy tissue, use 3-5 cores block or stacked slides should be at least 1 mm<sup>3</sup>. 5x 5 mm or 2.5 x embedded in a single block, aligned so that If the surface area is 25 mm<sup>2</sup> as recommended, 10mm). when cut, the blade is running parallel to the the depth should be at least 40 microns. For this long axis of the cores. reason, a minimum of 12 slides is required. In OR addition, the specimen must • Fine needle aspirates with good cellularity are acceptable as long as cell blocks are contain a tumor volume established. $\geq 0.2 \text{ mm}^3$ .


## **NUCLEATED CELLULARITY** ≥ 80 %

metastatic sites. Bone biopsies are not allowed.

• Biopsy tissue can be from primary or

Specimens containing less than 80% nucleated cells require greater total volume and may not be suitable to assay. A total of 75,000 to 150,000 nucleated cells are recommended.





PRIOR TO ENROLLMENT, YOUR LOCAL PATHOLOGIST MUST SIGN OFF ON THE <a href="#state-of-

Questions? Email: \$1400question@crab.org

- Sites will receive up to \$5,869 (\$1,079 screening/\$4,790 registration) for each patient on trial
  - o Additional Site Payment for patients registered to <u>\$\$1400</u> of **\$\$500** for a limited duration.
- ❖ If biopsies are needed, sites will receive \$3,000/\$6,000 for the biopsies performed at screening and/or progression after initial response on Arm1
- Sites will be reimbursed for additional research based procedures
- Sites will be reimbursed \$1,333 for on-site visits outside the regular audit schedule

Funding Questions: SWOG Group Chair's Office, <a href="mailto:funding@swog.org">funding@swog.org</a>
For additional information, see funding memos

Eligibility / Data Submission	Protocol / Regulatory	Public Relations / Media
Louise Highleyman and Kara Amber Data Coordinators SWOG Data Operations Center (206) 652-2267 S1400Question@crab.org	Crystal Miwa Protocol Coordinator SWOG Operations Office (210) 614-8808 ext 1019 cmiwa@swog.org	Wendy Lawton SWOG Communications Manager SWOG Group Chair's Office (503) 348-8675 lawtonw@ohsu.edu
Specimen		Imaging
Fred R. Hirsch, MD, PhD Study Co-Chair (303) 724-3858 fred.hirsch@ucdenver.edu	Philip C. Mack, PhD Study Co-Chair (916) 734-8022 pcmack@ucdavis.edu	Lawrence H. Schwartz, MD Study Co-Chair (212) 305-8994 Ihs2120@cumc.columbia.edu

## **Specimen and Imaging Submission**

Foundation Medicine Inc. **TRIAD** 

(617) 418-2200 SWOG1400@irocohio.org

or call IROC Ohio at 614-293-2929 \$1400@foundationmedicine.com

## **USA Investigational Drug Distribution**

Pharmaceutical Management Branch (PMB)

Matthew Boron (240) 276-6575

PMBAfterHours@mail.nih.gov

#### **Funding**

Federal funding:

Pat Mize, MBA Accounting Specialist (503) 418-4533

mizep@ohsu.edu

Non-federal funding:

Casey Dawson Financial Administration: SWOG-CTI

(503) 494-5517 dawsoca@ohsu.edu Distribution Email: funding@swog.org

S1400 Treatment-related/Medical				
Vassiliki Papadimitrakopoulou, MD Study Chair (713) 792-6363 S1400MedicalQuery@swog.org	Roy S. Herbst, MD Study Co-Chair (203) 785-6879 S1400MedicalQuery@swog.org	David R. Gandara, MD Study Co-Chair (916) 734-3771 S1400MedicalQuery@swog.org		
Sub-Study Treatment- related/ Medical	Study Chair	Study Co-Chair		
S1400A S1400AMedicalQuery@swog.org	Vassiliki A. Papadimitrakopoulou, MD NCTN Group: SWOG (713) 792-6363	Hossein Borghaei, DO NCTN Group: ECOG-ACRIN (215) 214-4297		
S1400B S1400BMedicalQuery@swog.org	Corey J. Langer, MD NCTN Group: NRG (215) 615-5121	James L. Wade III, M.D. NCTN Group: SWOG (217) 876-6600		
S1400C S1400CMedicalQuery@swog.org	Martin J. Edelman, MD NCTN Group: ALLIANCE (410) 328-8708	Kathy S. Albain, MD NCTN Group: SWOG (708) 327-3102		
S1400D S1400DMedicalQuery@swog.org	Charu Aggarwal, MD, MPH NCTN Group: ECOG-ACRIN (215) 662-6318	Primo N. Lara, Jr., MD NCTN Group: SWOG (916) 734-5959		
S1400E S1400EMedicalQuery@swog.org	Mark A. Socinski, MD NCTN Group: ALLIANCE (412) 692-4724			
S1400IMedicalQuery@swog.org	Scott N. Gettinger, M.D. NCTN Group, SWOG (203) 785-7564	Lyudmila A. Bazhenova, M.D. NCTN Group: Alliance (858) 822-6189		
S1400G S1400GMedicalQuery@swog.org	Taofeek K. Owonikoko, M.D., Ph.D. MSCR NCTN Group, ECOG-ACRIN (404) 778-5575	Lauren A. Byers, M.D. NCTN Group: SWOG (713) 792-6363		